Karuna Therapeutics, Inc. (KRTX) — Financial statements
Income statement, balance sheet, and cash flow for Karuna Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.65↓93.9% | 11↓71.2% | 37 | 0.00 | 0.00 | |
| Cost of Revenue | 2↑53.0% | 1↑119.8% | 0.51↑249.0% | 0.15↑150.0% | 0.06 | |
| Gross Profit | -1↓111.0% | 10↓73.9% | 36↑25243.4% | -0.15↓150.0% | -0.06 | |
| Operating Expenses | ||||||
| R&D Expenses | 364↑62.4% | 224↑74.9% | 128↑195.3% | 43↑76.9% | 25 | |
| General & Administrative Expenses | 131↑72.7% | 76↑44.6% | 53↑85.2% | 28↑36.1% | 21 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 131↑72.7% | 76↑44.6% | 53↑85.2% | 28↑36.1% | 21 | |
| Other Expenses | 0.59↑1.4% | 0.58↑128.3% | 0.25 | 0.00 | 0.00 | |
| Operating Expenses | 495↑65.0% | 300↑66.1% | 181↑151.8% | 72↑58.2% | 45 | |
| Total Costs & Expenses | 495↑65.0% | 300↑66.1% | 181↑151.8% | 72↑58.2% | 45 | |
| Operating Results | ||||||
| Operating Income | -495↓70.8% | -290↓101.4% | -144↓100.3% | -72↓58.2% | -45 | |
| Depreciation & Amortization | 2↑53.0% | 1↑58.4% | 0.70↓78.8% | 3↑30.7% | 3 | |
| EBITDA | -493↓89.9% | -260↓81.4% | -143↓108.9% | -69↓59.8% | -43 | |
| EBIT | -495↓89.8% | -261↓81.3% | -144↓100.3% | -72↓67.0% | -43 | |
| Interest & Other Income | ||||||
| Net Interest Income | 61 | 0.00↓100.0% | 0.50↓84.8% | 3↑108.8% | 2 | |
| Interest Income | 61↑331.5% | 14↑2724.3% | 0.50↓84.8% | 3↑30.7% | 3 | |
| Interest Expense | 0.00↓100.0% | 14 | 0.00 | 0.00↓100.0% | 0.95 | |
| Non-Operating Income | 0.00↑100.0% | -29 | 0.00 | 0.00↑100.0% | -2 | |
| Other Income / Expenses | 62↑318.5% | 15↑27229.6% | 0.05↓98.4% | 3↑128.2% | 1 | |
| Income Before Tax | -433↓57.5% | -275↓91.2% | -144↓109.9% | -69↓55.9% | -44 | |
| Income Tax Expense | 0.67↓52.8% | 1↑23533.3% | 0.01↓86.0% | 0.04↓95.2% | 0.89 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -434↓56.9% | -276↓92.2% | -144↓109.8% | -69↓52.9% | -45 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -434↓56.9% | -276↓92.2% | -144↓109.8% | -69↓52.9% | -45 | |
| Bottom-Line Net Income | -434↓56.9% | -276↓92.2% | -144↓109.8% | -69↓52.9% | -45 | |
| EPS (Basic) | -11.73↓34.2% | -8.74↓76.9% | -4.94↓90.7% | -2.59↑30.9% | -3.75 | |
| EPS (Diluted) | -11.73↓34.2% | -8.74↓76.9% | -4.94↓90.7% | -2.59↑30.9% | -3.75 | |
| Weighted Average Shares | 37↑16.9% | 32↑8.5% | 29↑10.2% | 26↑121.2% | 12 | |
| Weighted Average Diluted Shares | 37↑16.9% | 32↑8.5% | 29↑10.2% | 26↑121.2% | 12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.